The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long term effects of treatment with dabrafenib (D) and/or trametinib (T) in pediatric patients with MAPK pathway-activated tumors.
 
Eric Bouffet
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Fore Biotherapeutics; Ipsen; Servier
Research Funding - Roche (Inst)
 
Dong-Anh Khuong-Quang
Research Funding - Day One, BluePrint, Novartis, Bayer
 
Antonio Verrico
No Relationships to Disclose
 
Junichi Hara
Consulting or Advisory Role - Ohara Pharmaceutical
 
Ashley Plant
No Relationships to Disclose
 
Isabelle Aerts
No Relationships to Disclose
 
Angela Mastronuzzi
Employment - IRCCS OSPEDALE PEDIATRICO BAMBINO GESU'
Consulting or Advisory Role - Ipsen
 
Jasper van der Lugt
No Relationships to Disclose
 
Ludmila Papusha
No Relationships to Disclose
 
Felix Sahm
Stock and Other Ownership Interests - Heidelberg Epignostix GmbH
Honoraria - Illumina; Ipsen; MedSIR; SERVIER
Consulting or Advisory Role - Illumina; Ipsen; MedSIR; SERVIER
Speakers' Bureau - Illumina; Ipsen; SERVIER
Patents, Royalties, Other Intellectual Property - Heidelberg Epignostix; Heidelberg University
 
Uri Tabori
No Relationships to Disclose
 
Kenneth Cohen
Consulting or Advisory Role - Day One Biopharmaceuticals
 
Roger Packer
Consulting or Advisory Role - Day 101
 
Olaf Witt
Honoraria - Day One Biopharmaceuticals (Inst); Ipsen; Novartis; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; BMS; Day One Biopharmaceuticals; Day One Therapeutics; Ipsen; Janssen Research & Development (Inst); Merck KGaA; Novartis; Novartis; Roche; SK Life Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Day One Biopharmaceuticals (Inst); Day One Therapeutics (Inst); GlaxoSmithKline (Inst); Janssen Research & Development (Inst); Lilly (Inst); Loxo (Inst); Loxo/Bayer (Inst); Novartis (Inst); PreComb Therapeutics (Inst); Roche Pharma AG (Inst)
 
Michael Roughton
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Megan Carnell
Employment - Novartis
 
Olga Ajipa
Employment - Novartis
 
Xin Liu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Mark Russo
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Darren Hargrave
Honoraria - Alexion Pharmaceuticals; AstraZeneca/MedImmune; Bayer; Day One Biopharmaceuticals; Ipsen; SpringWorks Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Biodexa; Boehringer Ingelheim; Day One Biopharmaceuticals; Ipsen; Novartis; Roche/Genentech; SpringWorks Therapeutics
Speakers' Bureau - Alexion Pharmaceuticals
Research Funding - AstraZeneca
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Boehringer Ingelheim; Novartis; Roche/Genentech
Other Relationship - Abbvie; AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Day One Therapeutics; Epizyme; Novartis